Dhanuka Agritech Ltd
NSE:DHANUKA
Dhanuka Agritech Ltd
Dhanuka Agritech Ltd. is a holding company, which manufactures agro-chemicals. The company is headquartered in Gurgaon, Haryana and currently employs 969 full-time employees. The company went IPO on 2011-06-28. The firm offers a range of product categories, including Herbicides, such as TARGA SUPER, NABOOD, SAKURA, DHANUTOP, WEEDMAR SUPER, NOWEED, BARRIER and OZONE; Fungicides, such as LUSTRE, GODIWA SUPER, Vitavax, VITAVAX POWER and HEXADHAN PLUS; Insecticides, such as FOSTER, CALDAN 4 G, CALDAN 50 SP, FAX SC, APPLE, AREVA SUPER, MARKAR and MEDIA SUPER, and Plant Growth Regulators, such as WETCIT, SUELO, DHANVARSHA and DHANZYME GOLD GRANULES. The firm offers its crop solutions for various crops, such as cotton, paddy, wheat, sugarcane, pulses, fruits & vegetables, plantation crops and others. The firm's subsidiaries include Dhanuka Agri-solutions Private Limited and Dhanuka Chemicals Private Limited.
Dhanuka Agritech Ltd. is a holding company, which manufactures agro-chemicals. The company is headquartered in Gurgaon, Haryana and currently employs 969 full-time employees. The company went IPO on 2011-06-28. The firm offers a range of product categories, including Herbicides, such as TARGA SUPER, NABOOD, SAKURA, DHANUTOP, WEEDMAR SUPER, NOWEED, BARRIER and OZONE; Fungicides, such as LUSTRE, GODIWA SUPER, Vitavax, VITAVAX POWER and HEXADHAN PLUS; Insecticides, such as FOSTER, CALDAN 4 G, CALDAN 50 SP, FAX SC, APPLE, AREVA SUPER, MARKAR and MEDIA SUPER, and Plant Growth Regulators, such as WETCIT, SUELO, DHANVARSHA and DHANZYME GOLD GRANULES. The firm offers its crop solutions for various crops, such as cotton, paddy, wheat, sugarcane, pulses, fruits & vegetables, plantation crops and others. The firm's subsidiaries include Dhanuka Agri-solutions Private Limited and Dhanuka Chemicals Private Limited.
Revenue Decline: Q3 revenue fell to INR 409.92 crores from INR 445.27 crores a year ago, reflecting weak agrochemical demand and adverse weather impacts.
Profit Drop: Profit after tax dropped to INR 40 crores in Q3, down from INR 55.04 crores last year, hit by continued industry-wide volume declines.
Margin Pressure: EBITDA margin decreased, with Q3 EBITDA at INR 58.66 crores versus INR 75.56 crores last year; management expects annual EBIT margin to decline by around 100–110 bps.
Weak Demand Drivers: Lower crop prices, delayed purchases by farmers, and extended rainfall hurt overall demand, particularly in South and West India.
Outlook Improving: Management says the "bad phase is over," with Q4 starting strong and optimism for a recovery into rabi and kharif seasons.
Bayer Product Revenue: Revenue from Bayer-acquired molecules for 9 months was INR 25–27 crores, mainly domestic; annual total expected below earlier INR 40 crores guidance.
Biostimulant Impact: Regulatory changes led to a 9-month sales impact of INR 49 crores in biostimulants; management hopes to regain most of this in FY '27 as approvals are expected soon.
Dahej Plant Update: Second product commercialized; targeting 80% capacity utilization and EBITDA positive operations in FY '27.
Cash Position: Cash and liquid investments are above INR 250 crores, with inventory up due to slower sales.
